PD-L1 Inhibitors Market Held Nearly USD 36 Billion in 2023, Led by KEYTRUDA and OPDIVO Dominance | DelveInsight

DelveInsight's "PD-L1 Inhibitors Market Insight, Epidemiology and Market Forecast - 2034" report delivers an in-depth analysis of PD-L1 inhibitors epidemiology, market, and clinical development understanding of PD-L1 inhibitors in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Explore the intricate details of the PD-L1 Inhibitors Market Report @ https://www.delveinsight.com/report-store/pd-L1-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from PD-L1 Inhibitors Market Report
• The PD-L1 inhibitors market size in the 7MM was nearly USD 36 billion in 2023, with the United States generating the largest share, at nearly USD 26 billion.
• Clinical trials testing PD-L1 inhibitors have tripled in recent years, with more than 4,400 clinical trials, of which more than 3,600 are ongoing; nearly 90% of new trials started in 2020 are combination strategies.
• KEYTRUDA dominates the US PD-L1 inhibitors market, while OPDIVO leads in Japan, having regained its top position there after KEYTRUDA briefly overtook it.
• LIBTAYO is the market leader for non-melanoma skin cancers such as cutaneous squamous cell carcinoma and basal cell carcinoma, while TECENTRIQ holds the leading position in small-cell lung cancer.
• KEYTRUDA and OPDIVO (IV) patents are set to expire in the US in 2028, which is expected to significantly affect the market as emerging players struggle to fully replace their dominance.
• Bristol Myers Squibb has developed a subcutaneous formulation of OPDIVO to address the biosimilar impact, with patent expiry for the SC formulation set for 2030.
• The PD-L1 segment in China has been growing rapidly, with companies attempting to market their products in developed and other foreign markets.
• In September 2024, Roche received FDA approval for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first PD-L1 inhibitor available for subcutaneous injection, cutting administration time to about seven minutes compared to 30-60 minutes for the traditional IV infusion.
• The PD-L1 Inhibitors Companies include Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Regeneron, Pfizer, Novartis, and others.
• Promising PD-L1 Inhibitors therapies in the pipeline include spartalizumab, sasanlimab, zimberelimab, sugemalimab, HLX10, INCB99280, balstilimab, and others.

Get a Free sample for the PD-L1 Inhibitors Market Forecast, Size & Share Analysis Report @ https://www.delveinsight.com/sample-request/pd-L1-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What are PD-L1 Inhibitors?
PD-1 is a checkpoint protein found on T cells that acts as a type of "off switch," helping keep T cells from attacking other cells in the body, especially when it attaches to PD-L1, a protein found on some normal and cancer cells. Some cancer cells carry large amounts of PD-L1, which helps them evade immune attack. Monoclonal antibodies that target either PD-1 or PD-L1 can block this binding and boost the immune response against cancer cells. Drugs that target PD-1 include KEYTRUDA, OPDIVO, LIBTAYO, JEMPERLI, ZYNYZ, LOQTORZI, and TEVIMBRA, while drugs that target PD-L1 include TECENTRIQ, BAVENCIO, and IMFINZI. Immune checkpoint inhibitors have revolutionized cancer care over the last decade, offering an alternative to chemotherapy and a chance at long-term remission across many tumor types, and their use has expanded from metastatic cancers into early-stage disease, such as triple-negative breast cancer and non-small-cell lung cancer.

PD-L1 Inhibitors Market Segmentation
• Region
• Therapies
• Analysis (KOL Views, SWOT Analysis, Reimbursement, Unmet Needs)

Download the report to understand which factors are driving the PD-L1 Inhibitors market trends @ https://www.delveinsight.com/report-store/pd-L1-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

PD-L1 Inhibitors Approved Therapies
• KEYTRUDA (pembrolizumab): Merck - A PD-1-blocking antibody approved for multiple cancer types, first approved in September 2014 for advanced melanoma. Its most recent approval, in January 2024, covers FIGO 2014 Stage III-IVA cervical cancer. With approval across 20 indications, KEYTRUDA holds the largest PD-L1 market share, though its US patent is set to expire in 2028.
• OPDIVO (nivolumab): Ono Pharmaceuticals and Bristol Myers Squibb - First approved in December 2014 for unresectable or metastatic melanoma. It dominates the Japan market and leads in indications such as melanoma, renal cell carcinoma, NSCLC, and gastric cancer, the latter being its top revenue driver in Japan.
• TECENTRIQ (atezolizumab): Genentech - First approved in May 2016 for urothelial carcinoma; holds the leading position in small-cell lung cancer.
• BAVENCIO (avelumab): Merck KGaA - First approved in March 2017 for metastatic Merkel cell carcinoma.
• IMFINZI (durvalumab): AstraZeneca - A human monoclonal antibody that binds PD-(L)1 and blocks its interaction with PD-1 and CD80, first approved in February 2018 for Stage III NSCLC. It is approved across four indications (NSCLC, ES-SCLC, BTC, and HCC) and reached approximately USD 4 billion in worldwide sales in 2023, with the majority from NSCLC. In June 2025, Imfinzi combined with FLOT chemotherapy showed a statistically significant and clinically meaningful improvement in event-free survival versus chemotherapy alone in resectable, early-stage and locally advanced gastric and GEJ cancers.

PD-L1 Inhibitors Pipeline Analysis
• Sasanlimab: Pfizer - A humanized IgG4 monoclonal antibody targeting the PD-1 receptor, currently in the pivotal Phase III CREST trial in combination with BCG for BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). Positive topline results were announced in January 2025, with further results reported in April 2025.
• HLX43: Shanghai Henlius Biotech - A leading PD-L1-targeting ADC progressing to Phase II development globally, with IND approvals from China's NMPA and the US FDA. It is being investigated across NSCLC, thymic squamous cell carcinoma, hepatocellular carcinoma, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, cervical cancer, and nasopharyngeal cancer. In June 2025, the first subject was dosed in HLX43-NSCLC201, a Phase II international multicenter trial for advanced NSCLC.
• Other emerging PD-L1 inhibitors: Spartalizumab (Novartis), Zimberelimab (Arcus Biosciences), Sugemalimab (EQRx/CStone Pharmaceuticals), HLX10 (Shanghai Henlius Biotech), Balstilimab (Agenus), envafolimab, and others.

PD-L1 Inhibitors Companies
Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Regeneron, Pfizer, Novartis, Ono Pharmaceuticals, Merck KGaA, Shanghai Henlius Biotech, Arcus Biosciences, Agenus, and others

PD-L1 Inhibitors Market Outlook
PD-1 inhibitors are expected to remain the leading drug class by sales, with PD-L1 therapies transforming cancer treatment across tumor types and stages due to their versatility as monotherapy or in combination with tyrosine kinase inhibitors, chemotherapy, or other immunotherapies. This has led to durable tumor responses and improved survival while maintaining acceptable toxicity profiles, allowing PD-L1 therapies to serve as a backbone in a wide range of combination regimens. Development of targets beyond PD-L1, such as TIGIT and TIM-3, has faced setbacks after high-profile failures, though both remain in development alongside LAG-3 and differentiated approaches like MHC Class II agonism. With the crowded PD-L1 landscape, differentiation and first-in-class positioning in new indications will be key for companies to stand out. Among the 7MM, the United States held the largest PD-L1 inhibitors market size in 2023, followed by Germany and the UK among EU4 markets.

Scope of the PD-L1 Inhibitors Market Report
• Study Period: 2020-2034
• Forecast Period: 2024-2034
• Coverage: 7MM (US, EU4, UK, and Japan)
• PD-L1 Inhibitors Companies: Merck, Bristol Myers Squibb, Genentech, AstraZeneca, Regeneron, Pfizer, Novartis, and others
• PD-L1 Inhibitors Therapies: KEYTRUDA, OPDIVO, TECENTRIQ, BAVENCIO, IMFINZI, and others
• PD-L1 Inhibitors Treatment Market: Current marketed and emerging PD-L1 inhibitor therapies
• Competitive Intelligence Analysis: SWOT Analysis
• PD-L1 Inhibitors Market Access and Reimbursement, Unmet Needs, and KOL Views

To know more about PD-L1 Inhibitors companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/pd-L1-inhibitors-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Contents
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF PD-(L)1 INHIBITORS
4. KEY EVENTS
5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
6. PD-(L)1 INHIBITORS MARKET OVERVIEW AT A GLANCE IN THE 7MM
7. PD-(L)1 INHIBITORS BACKGROUND AND OVERVIEW
8. EPIDEMIOLOGY AND PATIENT POPULATION
9. MARKETED DRUGS
10. EMERGING DRUGS
11. PD-(L)1 INHIBITORS: THE 7MM ANALYSIS
12. UNMET NEEDS
13. SWOT ANALYSIS
14. KOL VIEWS
15. MARKET ACCESS AND REIMBURSEMENT
16. APPENDIX
17. DELVEINSIGHT CAPABILITIES
18. DISCLAIMER
19. ABOUT DELVEINSIGHT

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.